Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901650 | 0.85 | — | — | |
| SCHEMBL3801577 | 0.85 | — | — | |
| SCHEMBL25286860 | 0.81 | ALDH1A1 (0.31) | CYP2C9ALDH1A1TSHRSOAT1 | |
| SCHEMBL2703448 | 0.80 | — | — | |
| SCHEMBL1597955 | 0.79 | SOAT1 (0.44) | CYP2C9ALDH1A1LMNASOAT1 | |
| SCHEMBL1398170 | 0.79 | CA1 (0.38) | CYP2C9ALDH1A1TSHRSOAT1 | |
| SCHEMBL5492354 | 0.78 | — | — | |
| SCHEMBL13520926 | 0.78 | — | — | |
| SCHEMBL10789620 | 0.75 | — | — | |
| SCHEMBL10031543 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013057593-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-25 | — | — | WO | claimed |
| WO-2013050884-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-11 | — | — | WO | claimed |
| CN-113292489-B | Preparation method of dichlorodialkyl nicotinonitrile | 泓博智源(开原)药业有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-113292489-A | Preparation method of dichlorodialkyl nicotinonitrile | 泓博智源(开原)药业有限公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2013057593-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057593-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013050873-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050873-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050884-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050884-A1 | PROCESS FOR THE PREPARATION OF LERSIVIRINE | PHIVCO UK LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003057674-A1 | 4-SULFIDE / SULFOXIDE / SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002004424-A9 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032184-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | CYP2C9 59/4885ALDH1A1 228/4885TDP1 71/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | CYP2C9 248/4885ALDH1A1 385/4885TDP1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.